Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Bristol-Myers, Sanofi ordered to pay Hawaii $834 million over Plavix warning label

Published 02/15/2021, 06:27 PM
Updated 02/15/2021, 11:05 PM
© Reuters. FILE PHOTO:  Bottles of Plavix shown on display at a pharmacy in North Aurora, Illinois.
BMY
-
SNY
-

By Tina Bellon and Nate Raymond

(Reuters) - A judge in Hawaii on Monday ordered Bristol-Myers Squibb (NYSE:BMY) Co and Sanofi (NASDAQ:SNY) SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from its blood thinner Plavix.

Judge Dean Ochiai in Honolulu concluded the companies engaged in unfair and deceptive business practices from 1998 to 2010 by failing to change the drug's label to warn doctors and patients despite knowing some of the risks.

Hawaii Attorney General Clare Connors, whose office sued the companies in 2014, said the ruling "puts the pharmaceutical industry on notice that it will be held accountable for conduct that deceives the public and places profit above safety."

Bristol-Myers and Sanofi, which produced Plavix in a partnership, in a joint statement vowed to appeal, saying the decision was "unsupported by the law and at odds with the evidence at trial." They called Plavix safe and effective.

Ochiai, who presided over a four-week, non-jury trial conducted entirely over Zoom due to the COVID-19 pandemic, ordered Bristol-Myers and Sanofi to each pay $417 million in penalties.

Hawaii alleged the companies violated state consumer protection laws by marketing Plavix without disclosing that the drug could have a diminished or no effect for some people, particularly of East Asian and Pacific Island ancestry.

Plavix is prescribed to prevent strokes and heart attacks. The blood thinner needs to be activated by the body's own enzymes, which can vary genetically.

Studies have shown that about 14% of Chinese patients are unable to metabolize the drug properly, compared with 4% of Black and 2% of white patients.

The U.S. Food and Drug Administration in 2010 issued a new Plavix warning label to reflect that information.

© Reuters. FILE PHOTO:  Bottles of Plavix shown on display at a pharmacy in North Aurora, Illinois.

Bristol-Myers and Sanofi still face a similar lawsuit over Plavix by the state of New Mexico.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.